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Why are 50,000–55,000 people dying
from rabies worldwide each year, with
25,000–30,000 human deaths in India
alone and over 3 billion people continuing
to be at risk of rabies virus infection in
over 100 countries in the 21
st century?
These are astonishing numbers, particu-
larly as they represent individuals, a large
proportion of whom are children, who
have been attacked or are likely to be
attacked by rabid dogs, the main source of
rabies virus infection that, as yet, has not
been brought under control in many parts
of the world. The number of human
deaths and the circumstances by which
these deaths continue to occur are ex-
traordinary, with over 95% of rabies
victims reported residing in Asia and
Africa and nearly all victims of a rabid
dog bite. Rabies has been part of the
history of civilization for several millennia,
rooted in its enzootic environment (animal
host) and causing severe threats to public
health across continents. Rabies and the
symptoms it presents can hardly be
ignored, yet it appears to be unduly
neglected in some parts of the world,
notably in Asia and Africa, where the
spread of canine rabies is not under
control and is far from being eliminated.
In other parts of the world, largely in
developed countries, where elimination of
canine rabies has been achieved, there are
models to be followed and lessons learned
that will challenge epidemiologists and
molecular virologists alike in the future as
they apply new techniques to achieve the
elimination of canine and human rabies
worldwide.
Through the World Rabies Day (WRD)
initiative (www.worldrabiesday.org), over
55 million people have received educa-
tional material about rabies prevention.
Today, people from more than 85 coun-
tries are involved on all levels of society
(government, medical and veterinary pro-
fessionals, media, educators, and lay
people), ready to take some action toward
elimination of endemic rabies worldwide.
Despite the many languages and different
cultures involved and so little money to
work with, the empowerment of people
around the world to do something for their
own communities and countries is what
has made the WRD initiative successful.
Educational materials have been created
that are easily translated into different
languages and distributed through elec-
tronic media, and with these materials
people are becoming better educated
about rabies prevention. People are learn-
ing that going to local healers for treat-
ments that do not work, such as rubbing
chili powder in wounds, incantations, and
taking ineffective herbal medicines, is not
the way to prevent rabies. Instead, people
learn from the educational materials that
the risk of exposure to rabies can be
minimized and the disease can be pre-
vented by using the right methods and
treatments, and together these measures
can make a difference in their own lives.
In several recent PLoS Neglected Tropical
Diseases papers on rabies (2009–2010)—
marking the third anniversary of World
Rabies Day—scientists describe the situa-
tion of canine rabies control in developing
countries, as well as various recent advanc-
es in the development of vaccines and
treatments for rabies that will contribute to
the elimination of human deaths from
rabies. Reduction in the number of human
deaths due to rabies has to begin with the
elimination of canine rabies in these
countries. The feasibility of eliminating
canine rabies in Africa [1] is predicated
on the understanding and counteracting of
the many reasons that canine rabies control
has failed in Africa. It is interesting that the
authors conclude that there are no reasons,
nor any insurmountable problems, that
would prevent canine rabies control from
being achievable in most of Africa. In one
of the papers, the authors state, ‘‘elimina-
tion of canine rabies is epidemiologically
and practically feasible through mass
vaccination of domestic dogs; and that
domestic dog vaccination provides a cost-
effective approach to the prevention and
elimination of human rabies deaths’’ [1].
The lessons learned from epidemiolog-
ical studies and the development of spatial
models forecasting animal susceptibilities
to enzootic rabies might be used for
prevention and control of canine rabies,
as well as other emerging zoonoses, in
rabies endemic areas of the world [2].
With better surveillance methods for
predicting newly emerging rabies epizoot-
ics through an understanding of the spatial
dynamics and actual spread of enzootic
rabies by any given host species, it would
seem that the application of subsequent
interventions, such as a vaccination pro-
gram, can be improved. Conducting
coordinated wildlife rabies management
programs, particularly those relying heavi-
ly on oral rabies vaccination strategies,
requires substantial interjurisdictional col-
laboration. For example, recent advances
in coordinated surveillance practices, re-
ferred to as ‘‘enhanced rabies surveil-
lance’’ and involving search and control
measures, have greatly facilitated detection
of animal rabies cases in a number of
border areas shared by Canada, Mexico,
and the United States, and have led to
definitive actions for controlling rabies in
strategically key areas [3]. At the basis of
rabies control strategies are the validated
diagnostic tests for rabies virus or a
lyssavirus variant (there are at least six
lyssavirus genotypes in addition to the
rabies virus genotype). The molecular
tools, which are readily accessible and
easily used for detection of viral RNA and
even species-specific viral RNA sequences,
are becoming more widely accepted for
the diagnosis of rabies [4]. Above all, in
developing countries, diagnostic laborato-
ries must operate under the precept that
the lower the cost and the greater the
‘‘artlessness’’ of the molecular diagnostic
tool, the better the chance that modern
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diagnosis of rabies. In their review [4],
Fooks et al. describe some of the latest
developments and diagnostic techniques
for determining the presence of rabies
virus or nucleic acid in diagnostic samples.
The authors write, ‘‘In the 21
st century, it
is expected that diagnostic virology tech-
niques for high throughput rabies virus
detection will progress rapidly towards the
use of molecular diagnostics replacing
more conventional testing techniques such
as virus isolation and histopathology’’ [4].
Vaccination is the most effective meth-
od of pre- or post-exposure medical
intervention against rabies. What is clearly
different and crucial in the case of human
rabies is that, compared to any other
human or animal pathogen-induced dis-
ease, it is the most severe of all infectious
diseases, to the point of being almost
invariably fatal. Fortunately, safe and
efficacious commercially prepared cell
culture-based vaccines are available to
prevent rabies. The downside of most of
these vaccines for use in the developing
world is that they are too costly to produce
and they have to be administered repeat-
edly—three times for pre-exposure vacci-
nation and four or five times for post-
exposure prophylaxis (PEP). In addition,
for the more severe exposures, a regimen
of vaccine combined with inoculations of
rabies immunoglobulin (RIG) of human
(HRIG) or equine (ERIG) origin for
passive protection is required [5]. What
the countries of the developing world need
instead is an exceedingly inexpensive
(compared to the cost of current conven-
tional vaccines), safe vaccine that will
provide sustained protection, preferably
from a single dose. It is the goal of
scientists in the 21
st century to develop
novel rabies vaccines for use in humans.
Many of these novel vaccines have advan-
tages and disadvantages in their current
stages of development compared to the
cell culture-based vaccines currently in
clinical use [5]. Nevertheless, advances are
being made with the use of recombinant
and reverse genetics techniques to con-
struct highly immunogenic (immunogenic-
ity that is increased by insertion of one or
more additional glycoprotein genes), fully
attenuated (for safety) rabies virus vaccines
that can be scaled up in cell culture
systems at low cost. Thus far, several of
these novel vaccine candidates, which
have gone through preclinical testing in
laboratory animals, show considerable
promise for achieving protection in mice
with a single moderate dose of the vaccine.
They are, however, several years away
from possible acceptance for use in
humans. Just as rabies vaccines are going
through a revolutionary development pro-
cess, new types of adjuvants are being
evaluated, which, at least in mice, have a
dose-sparing effect [5]. Whether transgen-
ic plants will eventually be a suitable host
and provide sizeable crops for production
of subunit proteins of rabies virus as edible
or nonedible vaccines is also under
investigation, as are naked DNA vaccines.
Plasmid DNA or replicon-based self-repli-
cating DNA vaccines have the clear
advantage of being easy to generate and
produce in large amounts. They are likely
to be more cost-effective to produce than
purified subunit vaccines that require
mammalian cell culture systems for pro-
duction, but their effectiveness (immuno-
genicity and ability to protect) against
rabies in humans has not yet been fully
determined. The slow onset of an immune
response to the transgene product of a
DNA vaccine makes their usefulness for
PEP doubtful. Other candidates in the
arsenal of novel rabies vaccines currently
under investigation include the recombi-
nant heterologous viral vectors, such as
various types of poxvirus and adenovirus
vectors. Two novel recombinant poxviral
vector vaccines, one using the Copenha-
gen strain of vaccinia virus (V-RG) and the
other the canarypox virus (ALVAC), each
expressing the rabies virus glycoprotein,
are licensed and produced commercially
for oral immunization of wildlife (rac-
coons, coyotes, or cats). The V-RG
vaccine does not induce adequate protec-
tive immunity in other species such as
skunks and dogs when administered orally,
however, so alternative oral vaccines need
to be identified to target these species,
particularly dogs, since they serve as major
reservoirs for rabies worldwide, especially
in Asia and Africa. The modified vaccinia
virus Ankara (MVA) has been considered
a possible alternative, although prelimi-
nary observations suggest that when ad-
ministered orally, it fails to elicit anam-
nestic immune responses in dogs and
raccoons that have previously been vacci-
nated. Further work must continue in the
21
st century to find and develop these and
other new-generation oral vaccines for
animal species that are the reservoirs for
rabies.
Considerable attention has been direct-
ed in recent years to the recombinant
adenovirus (Ad)-based vectors that are
derived from different human Ad sero-
types and animal species serotypes for use
as vaccines [5]. A problem with using
human Ad serotypes arises, however, from
the fact that adenoviruses are common
pathogens in humans and it is highly
probable that an individual who is immu-
nized with a human Ad vector will already
have neutralizing antibodies to the Ad
vector. In such cases, the prevalence of
neutralizing antibodies in the host will
weaken the immune response to the
human Ad vector and the expressed
pathogen-specific gene product encoded
in the vector when given as a vaccine.
Therefore, an alternative Ad vector de-
rived from an animal species (unlikely to
have infected humans) may be considered
a more suitable vaccine carrier to protect
humans from rabies than the more
common human Ad serotypes. According-
ly, several alternative vaccine vectors
derived from chimpanzee adenoviruses
(AdC) are being tested, since most humans
are not likely to have neutralizing anti-
bodies to the AdC serotypes before
immunization with the AdC vectors as
vaccines [5]. Whether these novel vaccine
vectors will prove more suitable for large-
scale, low-cost prophylactic vaccination in
resource-poor countries and provide ade-
quate PEP (after exposure to a rabid
animal) with fewer doses of the vaccine
than are required with conventional vac-
cine regimens remains to be determined
with further investigation.
Knowing whether a person who re-
ceived a rabies vaccine will be protected
from a potentially lethal rabies virus
challenge is sometimes dependent solely
on the laboratory assessment of circulating
antibodies that the person developed
following immunization. The selection of
the appropriate assay(s) to assess an
individual’s antibody titer and the valida-
tion of the assay method used therefore
become extremely critical. For a fatal
disease like rabies, these considerations,
though often complex, are of paramount
importance. To adhere to the principle
that the appropriate assay will be used is
especially significant when the results from
such assays serve as a surrogate marker for
the expected level of disease prevention.
Laboratories that provide these important
diagnostic services throughout the world
need to pay special attention to the
standardization and validation of the
methods they use and should require
proficiency testing, training, and certifica-
tion of staff involved in performing such
tests [6].
One of the significant contributing
factors to the unacceptably high death
rate from human rabies in the developing
world is the severe shortage to nonexis-
tence of the recommended components of
PEP, HRIG, or ERIG. In the PEP
treatment of patients, it is critical that
RIG be administered with the initial dose
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animal to provide passive immunity to
neutralize virus at the wound site until
active immunity stimulated by the vaccine
takes over. With the increased demand for
post-exposure treatment in the developing
world, as in developed countries, the
world’s supply has failed to provide these
needed biological components. Replace-
ment of HRIG and ERIG with cheaper
and efficacious alternative biologicals for
treatment of rabies in humans is therefore
a high priority. Accordingly, cocktails of
mouse monoclonal antibodies (MuMAbs)
and human monoclonal antibodies (Hu-
MAbs) are presently being assessed as
replacements for RIG [7,8].
Development of antiviral biologics other
than MAbs for the therapeutic interven-
tion of human rabies has not received as
much attention as is warranted, mainly
because it has been so difficult to target a
virus that infects almost exclusively neu-
rons and replicates predominantly in
neurons of the central nervous system
(CNS). Recently, scientists started to
investigate one of the major characteristics
of pathogenic rabies virus: its ability to
suppress responses of the immune system
[9]. Being able to cross the BBB into the
CNS is key to having rabies virus–specific
antibody-producing B cells in the CNS
that are capable of neutralizing rabies
virus, and immune effector T cells and
molecules to clear rabies virus from the
CNS tissues. It is well known that the
neuropathogenesis of virulent, and not
attenuated, rabies virus is associated with
its ability to prevent delivery of immune
effector T cells and B cells across the BBB
to control virus replication and clear virus
from the CNS [10]. The possibility that
superinfection with an attenuated (live,
nonpathogenic) rabies virus, as a vaccine,
could be a new strategy for the treatment
of a pathogenic rabies virus infection after
the virus has reached the CNS and signs of
the disease have appeared is intriguing
[10].
The public worldwide continues to be at
risk of exposure to rabies, whether it be in
developing countries where control of
canine rabies has been largely neglected
or in developed countries where the
potential risk from enzootic rabies is
primarily from exposure to a variety of
wildlife animal species. Communicating
that risk is a matter of understanding
communication principles and stakeholder
responsibilities. The 74-country World
Rabies Day initiative launched in 2007
brought urgent attention to the need to
address the global threat of rabies more
strategically worldwide and for each coun-
try to act domestically. The excellent
example of the successful canine rabies
elimination within the United States that
was announced by the Centers for Disease
Control and Prevention (CDC) was
brought about over many decades by
local, state, and federal public health
authorities [11,12]. Also, collaboration
with the US Department of Agriculture,
which has been responsible for oral rabies
vaccination of wildlife in the US, repre-
sents an ongoing strategic activity to
reduce or eliminate enzootic rabies from
wildlife reservoirs. Many lessons can be
learned from the actions taken by local,
state, and federal authorities in the US in
their efforts to devise ‘‘risk communica-
tion’’ strategies. It is the hope of scientists,
public authorities, and veterinary and
medical professionals worldwide that it
will not take another century before one of
the most severe and often-neglected dis-
eases threatening animals and humans
alike is eliminated.
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